by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM) from the CEPHEUS trial. Read More
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Explore the complexities of managing toxicities in breast cancer treatments, including endocrine therapies, antibody drug conjugates, and immune checkpoint inhibitors. Read More
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Frank Qian, MD, MPH, discusses the integration of omega-3 fatty acid therapy alongside statins and PCSK9 inhibitors in cardiovascular risk management, highlighting the distinct mechanisms of benefit and lack of significant drug...
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction...
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates. Read More
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Gaps in curricula emphasize a need for enhanced interprofessional training to improve patient care. Read More